Cardarine — Safety, Research, Risks & Legal Status

Not medical advice. Cardarine is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	GW-501516, GW1516, endurobol
Category	SARM
cancer_signal	Multiple organ cancers at multiple sites in long-term rodent studies; primary reason for program termination
glaxosmithkline	Developed by GSK but abandoned before human approval
ppar_agonist_class	Related to other PPAR drugs used clinically, but GW-501516 selectivity profile differed
US legal status	Cardarine is not approved by the FDA for any use, and it is illegal to market or sell it as a dietary supplement. Products are sold as research chemicals not for human consumption, and the FDA has warned that SARM-type products carry serious risks. It is prohibited at all times in sport under the WADA list.

What is Cardarine?

Cardarine (GW-501516) is not actually a SARM but a PPAR-delta agonist that is commonly grouped and sold alongside SARMs. It was investigated for metabolic and endurance effects before development stopped.

How it works

Cardarine is a selective PPAR-delta (PPARdelta) agonist that activates peroxisome proliferator-activated receptor delta, a nuclear receptor regulating lipid and glucose metabolism. It influences fatty-acid oxidation and mitochondrial biogenesis pathways. The compound was designed to improve metabolic health, but off-target effects in animal models led to the discovery of cancer promotion in multiple tissues.

Background & history

Cardarine (GW-501516) was developed by GlaxoSmithKline as a PPAR-delta agonist for dyslipidemia and metabolic disorders in the late 1990s and 2000s. Early animal efficacy led to human trials, but long-term rodent carcinogenicity studies halted development; the compound was never approved and was abandoned due to cancer signals in preclinical safety work.

What the research says

Research suggests GW-501516 can affect fat metabolism and endurance in animal models. Critically, its development was halted after long-term animal studies showed it caused cancer in multiple organs, and there are no completed human safety trials.

Reported effects

Reported increases in endurance in animal studies
Studied effects on fat oxidation and metabolism
Reported reductions in body fat by users
Studied effects on cholesterol in early research
Reported enhanced vascularity by users
Studied metabolic rate changes in rodent models

Dosing & administration (informational)

Animal studies used doses ranging widely; human trial data are not in the public domain given the early halt. Any human dosing claims are purely speculative and lack supporting evidence. The cancer findings preclude any rational human dose-finding effort.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Development was discontinued after animal studies showed it caused cancer in several organs, which is the central safety concern
There are no completed human safety trials, so risks in people are unknown
Marketed as performance-enhancing despite the cancer findings, which is a serious red flag
Often sold mixed with genuine SARMs, compounding risks
Prohibited at all times in sport under the WADA list
May cause elevated liver enzymes and other metabolic derangements

Drug & supplement interactions

May interact with lipid-modifying drugs given overlapping PPAR pathways
Potential for additive metabolic stress if combined with other weight-loss or endurance compounds
Limited data on interactions with insulin or glucose-modulating agents
Unknown interactions with all pharmaceuticals given lack of human pharmacokinetics
Any use with other compounds adds unknowable risks beyond the baseline cancer concern

Who should avoid it

Avoid entirely given the cancer signal in animal studies, regardless of other factors
Avoid if there is personal or family history of cancer
Avoid in combination with any other compounds, particularly performance-enhancing agents
Avoid if planning to participate in sport or undergo workplace drug screening
Avoid without explicit, informed clinician awareness of carcinogenicity findings

How it is commonly combined

Cardarine is sometimes marketed as a stack component for endurance and fat loss, but stacking it with other compounds only multiplies unknown risks. Its cancer signal makes any use unjustifiable; combining it with other substances is irrational and potentially catastrophic.

Legal & regulatory. Cardarine is not approved by the FDA for any use, and it is illegal to market or sell it as a dietary supplement. Products are sold as research chemicals not for human consumption, and the FDA has warned that SARM-type products carry serious risks. It is prohibited at all times in sport under the WADA list.

Quality & harm reduction

A
t
h
i
r
d
-
p
a
r
t
y
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
(
C
O
A
)
c
a
n
n
o
t
m
a
k
e
a
c
o
m
p
o
u
n
d
w
i
t
h
c
a
n
c
e
r
f
i
n
d
i
n
g
s
s
a
f
e
,
b
u
t
i
t
c
a
n
c
o
n
f
i
r
m
w
h
a
t
i
s
i
n
a
p
r
o
d
u
c
t
a
n
d
v
e
r
i
f
y
a
b
s
e
n
c
e
o
f
o
t
h
e
r
c
o
n
t
a
m
i
n
a
n
t
s
.
I
n
d
e
p
e
n
d
e
n
t
l
a
b
a
n
a
l
y
s
e
s
f
r
e
q
u
e
n
t
l
y
f
i
n
d
t
h
e
s
e
p
r
o
d
u
c
t
s
m
i
s
l
a
b
e
l
e
d
o
r
c
o
n
t
a
i
n
i
n
g
u
n
l
i
s
t
e
d
d
r
u
g
s
o
r
S
A
R
M
s
m
i
x
e
d
i
n
.
A
n
y
u
s
e
s
h
o
u
l
d
i
n
v
o
l
v
e
c
l
i
n
i
c
i
a
n
o
v
e
r
s
i
g
h
t
a
n
d
i
n
f
o
r
m
e
d
a
w
a
r
e
n
e
s
s
o
f
t
h
e
c
a
n
c
e
r
s
i
g
n
a
l
.
T
r
e
a
t
u
n
r
e
g
u
l
a
t
e
d
p
r
o
d
u
c
t
s
a
s
p
o
t
e
n
t
i
a
l
l
y
c
o
n
t
a
m
i
n
a
t
e
d
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Does cardarine cause cancer?

Long-term animal studies showed GW-501516 caused cancer in multiple organs, which is why development was stopped. The human risk is not established, but this is a serious warning.

Is cardarine a SARM?

No. It is a PPAR-delta agonist, but it is commonly marketed and sold alongside SARMs.

What dose is safe?

We do not provide human dosing guidance, and given the cancer findings any use should be discussed with a qualified clinician.

Has cardarine been tested in humans?

Minimal human data exist; development halted before large trials due to cancer findings in animal work, and any products sold are entirely outside regulatory oversight.

Can cardarine improve athletic performance?

Animal models suggest metabolic effects, but human data are absent and the cancer signal makes any risk-benefit calculation impossible.

References & further reading

PubMed: GW-501516 PPAR-delta agonist cancer carcinogenicity
PubMed: cardarine GW501516 development halted safety concerns
FDA warning on SARMs and unapproved performance-enhancing compounds
WADA Prohibited List: PPARdelta agonists and metabolic modulators
GlaxoSmithKline development history and carcinogenicity findings